Guardant Health, INC Form 4 insider transactions

NASDAQ
Guardant Health Director Roberto Mignone reported the acquisition of 264 shares of common stock through the vesting of restricted stock units.
NASDAQ
Guardant Health Director Musa Tariq sold 348 shares of common stock at $88.09 per share under a pre-arranged trading plan.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina converted 232 restricted stock units into common stock on March 17, 2026.
NASDAQ
Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, reported multiple transactions involving common stock and restricted stock units, including vesting and tax-related dispositions.
NASDAQ
Guardant Health's Co-Chief Executive Officer, Helmy Eltoukhy, filed a Form 4 detailing planned equity transactions, including RSU vestings and new grants, scheduled for 2026.
NASDAQ
Guardant Health Director Tariq Musa converted 249 restricted stock units into common stock on March 15, 2026, as part of a pre-scheduled vesting.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of performance-based and standard restricted stock units, alongside a tax-related share disposition.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, vested a significant number of restricted stock units, acquiring common stock and selling a portion to cover tax obligations.
NASDAQ
Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of performance-based and time-based restricted stock units, alongside shares withheld for tax obligations.
NASDAQ
Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of performance-based restricted stock units and the subsequent disposition of shares for tax withholding.
NASDAQ
Guardant Health's CFO, Michael Brian Bell, reported the acquisition of common stock through RSU vesting and subsequent sales, adjusting his beneficial ownership.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, was granted 20,448 restricted stock units vesting over three years.
NASDAQ
Guardant Health, Inc. has granted 17,040 restricted stock units to Chief People Officer Terilyn J. Monroe, vesting over three years.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, received a grant of 13,632 Restricted Stock Units with a three-year vesting schedule.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, received a grant of 18,744 restricted stock units, aligning executive incentives with future company performance.
NASDAQ
Guardant Health's Chief Technology Officer, Darya Chudova, was granted 23,856 Restricted Stock Units with a three-year vesting schedule.
NASDAQ
Guardant Health's Chief Financial Officer, Michael Brian Bell, was granted 26,582 restricted stock units with a three-year vesting schedule.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, exercised stock options and subsequently sold a portion of the acquired shares.
NASDAQ
Guardant Health Director Steve Krognes converted 154 restricted stock units into common stock on February 28, 2026.
NASDAQ
Guardant Health Director Roberto Mignone converted 264 Restricted Stock Units into common stock, increasing his direct holdings.
NASDAQ
Guardant Health Director Steve Krognes reported the vesting of 154 restricted stock units, converting them into common stock.
NASDAQ
Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 8,571 shares of common stock for approximately $977,440 through a pre-arranged 10b5-1 plan.
NASDAQ
Guardant Health Director Roberto Mignone reported the acquisition of 264 shares of common stock and 264 restricted stock units.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina converted 232 restricted stock units into common stock on January 17, 2026.
NASDAQ
Guardant Health Director Musa Tariq acquired 250 shares of common stock and 250 restricted stock units on January 15, 2026, as part of a vesting schedule.
NASDAQ
Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
NASDAQ
Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 10,031 shares of common stock under a pre-arranged trading plan.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, increased his beneficial ownership of common stock through the vesting of restricted stock units and performance-based restricted stock units on January 1, 2026.
NASDAQ
Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and related tax-driven share disposals.